Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers

Eur J Drug Metab Pharmacokinet. Jul-Sep 1998;23(3):377-81. doi: 10.1007/BF03192297.


Relative bioavailability of cisapride was investigated after oral administration of a test versus a reference formulation of immediate release tablets of cisapride, both with 10 mg per unit. The study was conducted in a two-way cross-over design, as a single dose open-label randomised trial. The two formulations were administered in two treatment days , separated by a washout period of 6 days, in fasted subjects who received one single oral dose of 20 mg of one study medication of cisapride as two 10 mg tablets. Multiple samples were collected over 24 h post-dosing. Plasma samples were assayed for cisapride using a selective and sensitive high-performance liquid chromatography (HPLC) method with UV detection. The pharmacokinetic parameter values (mean+/-RSD%) of cisapride as the test formulation were: AUC0-infinity=329+/-20.9 ng.h/ml, Cmax=52.8+/-22.6 ng/ml, tmax=1.26+/-22.0 h and t1/2=4.08+/-15 h. Following administration of the reference formulation the values obtained for the same parameters were: AUC0-infinity=317+/-19.2 ng.h/ml, Cmax=49.2+/-21.3 ng/ml, tmax=1.38+/-30.1 h and t1/2=4.52+/-24.8 h. These results show that the two cisapride formulations can be considered as bioequivalent, with respect to the above mentioned parameters.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Analysis of Variance
  • Area Under Curve
  • Biological Availability
  • Cisapride / blood
  • Cisapride / pharmacokinetics*
  • Cross-Over Studies
  • Gastrointestinal Agents / pharmacokinetics*
  • Humans
  • Male
  • Tablets


  • Gastrointestinal Agents
  • Tablets
  • Cisapride